S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
OrthoPediatrics Corp. (NASDAQ:KIDS), a company specializing in surgical and medical instruments currently valued at $528 million, reported the results of its 2025 Annual Meeting of Stockholders held on May 23, 2025, in a recent SEC filing. The company’s stock has experienced significant pressure, declining 9% in the past week and currently trading near its 52-week low of $20.25. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 6.19.
During the annual meeting, shareholders elected directors to serve until the 2028 Annual Meeting or until their successors are duly elected and qualified. Votes were tallied for Fred L. Hite, Bryan W. Hughes, Samuel D. Riccitelli, and Mark C. Throdahl, with each director receiving a majority of votes for their election. The number of withheld votes and broker non-votes were also recorded for each nominee.
In addition, the stockholders approved, on an advisory basis, the compensation of the company’s named executive officers. The tally showed a significant majority in favor, with a minimal count against and a few abstentions, alongside broker non-votes.
The appointment of Deloitte & Touche LLP as the company’s Independent (LON:IOG) Registered Public Accounting Firm for the fiscal year ending December 31, 2025, was also approved by the shareholders. The accounting firm’s appointment received an overwhelming number of votes for, with a small number against and fewer abstentions.
The filing confirmed that all matters proposed at the meeting were approved by the company’s stockholders. The detailed results of the votes for each agenda item were included in the SEC Form 8-K submission. This information, based on the press release statement, provides a transparent view of the company’s governance and shareholder engagement. Looking ahead, InvestingPro data indicates analysts expect continued challenges, with a projected EPS of -$1.13 for fiscal year 2025. For deeper insights into OrthoPediatrics’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, OrthoPediatrics Corporation reported a 17% increase in revenue for the first quarter of 2025, reaching $52.4 million, surpassing the forecasted $51.68 million. This growth was driven by a 19% increase in U.S. revenue and an 11% rise in international sales. The company also received FDA approvals for several new products, enhancing its portfolio. OrthoPediatrics amended its acquisition agreement with Medtech Concepts, LLC, changing the payment method to unregistered shares of common stock valued at $3.75 million. Analysts from Stifel, BTIG, and Needham have maintained a Buy rating on the company, with price targets of $32, $38, and $42 respectively, reflecting confidence in OrthoPediatrics’ growth trajectory. Stifel and BTIG highlighted the company’s strong market presence and potential for sustained growth, while Needham noted OrthoPediatrics’ revenue beat and upward adjustment of its revenue outlook for 2025. The company anticipates positive free cash flow by the fourth quarter of 2025, signaling financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.